Status: Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

This is an open-label phase 1 study with an escalation part and an expansion part.

Participants needed: 200

Trial details

Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Abbisko Therapeutics Co, LtdUpdated: Apr 7, 2026Locations: 32

Eligibility criteria

Male or female, age 18 ~ 75 (include both ends, or other age range required by l... [+16]

Known allergy or hypersensitivity to any component of the investigational drug p... [+21]

Status: Recruiting

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma

Participants needed: 12

Trial details

Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Binhui Biopharmaceutical Co., Ltd.Updated: Dec 20, 2024Locations: 1

Eligibility criteria

Have fully understood the study and voluntarily signed the informed consent (the... [+18]

A history of pleural effusion related to moderate or severe ascites, hemorrhagic... [+21]

Status: Recruiting

Plasmodium Immunotherapy for Breast and Liver Cancers

The purpose of this study is to evaluate the safety and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced breast cancers and advanced liver cancers.The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.

Participants needed: 60

Trial details

Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: CAS Lamvac Biotech Co., Ltd.Updated: Feb 20, 2024Locations: 1

Eligibility criteria

18-70 years of age, male or female. [+9]

Patients with severe hemoglobin disease or severe G6PD deficiency; [+12]